نتائج البحث - "Andrić, Zoran"

المساهمون: Institut Català de la Salut, Andric Z Department of Medical Oncology, Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia. Gálffy G Pulmonology Hospital Törökbálint, Törökbálint, Hungary. Cobo Dols M Department of Medical Oncology, Hospital Regional Universitario de Málaga, Institute of Biomedical Research of Málaga (IBIMA), Málaga, Spain. Szima B Department of Pulmonology, Markusovszky Hospital, Szombathely, Hungary. Stojanovic G Institute of Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia. Petrovic M Clinic for Pulmonology, Clinical Center Kragujevac, Kragujevac, Serbia. Felip E Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Pulmons - Càncer - Tractament, Quimioteràpia combinada, Avaluació de resultats (Assistència sanitària), DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, Other subheadings::Other subheadings::/therapeutic use, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, Otros calificadores::Otros calificadores::/uso terapéutico, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento

وصف الملف: application/pdf

العلاقة: JTO Clinical and Research Reports;4(2); https://doi.org/10.1016/j.jtocrr.2022.100461Test; Andric Z, Gálffy G, Cobo Dols M, Szima B, Stojanovic G, Petrovic M, et al. Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC. JTO Clin Res Reports. 2023 Feb;4(2):100461.; https://hdl.handle.net/11351/9109Test

الإتاحة: https://doi.org/10.1016/j.jtocrr.2022.100461Test
https://hdl.handle.net/11351/9109Test

View record in BASE

النص الكامل

5

Evaluation of the efficiency and tolerability of mono therapy with oral etoposide in elderly patients (70+ years of age) with advanced non small cell lung cancer and poor performance status

المؤلفون: Andrić, Zoran, Kovčin, Vladimir, Crevar, Slobodanka, Murtezani, Zafir, Kostić, Sanja

المساهمون: Andrić, Zoran, Kovčin, Vladimir, Crevar, Slobodanka, Murtezani, Zafir, Kostić, Sanja

المصدر: European medical, health and pharmaceutical journal : open access reviewed journal | 2013 Volume:2013 | Number:6

الإتاحة: https://cdk.lib.cas.cz/client/handle/uuid:bmc14060595-5e8d6482-bf43-42cb-9f8e-46345cbb12e8Test
http://ojs.journals.cz/index.php/EMHPJ/issue/archiveTest

View record in Europeana

6

دورية أكاديمية

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

المساهمون: Peters, Solange, Dziadziuszko, Rafal, Morabito, Alessandro, Felip, Enriqueta, Gadgeel, Shirish M, Cheema, Parneet, Cobo, Manuel, Andric, Zoran, Barrios, Carlos H, Yamaguchi, Masafumi, Dansin, Eric, Danchaivijitr, Pongwut, Johnson, Melissa, Novello, Silvia, Mathisen, Michael S, Shagan, Sarah M, Schleifman, Erica, Wang, Jin, Yan, Mark, Mocci, Simonetta, Voong, David, Fabrizio, David A, Shames, David S, Riehl, Todd, Gandara, David R, Mok, Tony

مصطلحات موضوعية: Atezolizumab versus chemotherapy, NSCLC, blood-based tumor, mutational burden, phase 3 trial

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35995953; info:eu-repo/semantics/altIdentifier/wos/WOS:000842907100002; volume:28; issue:9; firstpage:1831; lastpage:1839; numberofpages:9; journal:NATURE MEDICINE; http://hdl.handle.net/2318/1874668Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85136993595

الإتاحة: https://doi.org/10.1038/s41591-022-01933-wTest
http://hdl.handle.net/2318/1874668Test

View record in BASE